These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

356 related articles for article (PubMed ID: 34899760)

  • 1. Advanced Imaging Techniques for Differentiating Pseudoprogression and Tumor Recurrence After Immunotherapy for Glioblastoma.
    Li Y; Ma Y; Wu Z; Xie R; Zeng F; Cai H; Lui S; Song B; Chen L; Wu M
    Front Immunol; 2021; 12():790674. PubMed ID: 34899760
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combination of IVIM-DWI and 3D-ASL for differentiating true progression from pseudoprogression of Glioblastoma multiforme after concurrent chemoradiotherapy: study protocol of a prospective diagnostic trial.
    Liu ZC; Yan LF; Hu YC; Sun YZ; Tian Q; Nan HY; Yu Y; Sun Q; Wang W; Cui GB
    BMC Med Imaging; 2017 Feb; 17(1):10. PubMed ID: 28143434
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Metabolic and physiologic magnetic resonance imaging in distinguishing true progression from pseudoprogression in patients with glioblastoma.
    Chawla S; Bukhari S; Afridi OM; Wang S; Yadav SK; Akbari H; Verma G; Nath K; Haris M; Bagley S; Davatzikos C; Loevner LA; Mohan S
    NMR Biomed; 2022 Jul; 35(7):e4719. PubMed ID: 35233862
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Advanced MRI assessment to predict benefit of anti-programmed cell death 1 protein immunotherapy response in patients with recurrent glioblastoma.
    Qin L; Li X; Stroiney A; Qu J; Helgager J; Reardon DA; Young GS
    Neuroradiology; 2017 Feb; 59(2):135-145. PubMed ID: 28070598
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Physiological Imaging Methods for Evaluating Response to Immunotherapies in Glioblastomas.
    Chawla S; Shehu V; Gupta PK; Nath K; Poptani H
    Int J Mol Sci; 2021 Apr; 22(8):. PubMed ID: 33918043
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Differentiation of Pseudoprogression from True Progressionin Glioblastoma Patients after Standard Treatment: A Machine Learning Strategy Combinedwith Radiomics Features from T
    Sun YZ; Yan LF; Han Y; Nan HY; Xiao G; Tian Q; Pu WH; Li ZY; Wei XC; Wang W; Cui GB
    BMC Med Imaging; 2021 Feb; 21(1):17. PubMed ID: 33535988
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combining cytotoxic and immune-mediated gene therapy to treat brain tumors.
    Curtin JF; King GD; Candolfi M; Greeno RB; Kroeger KM; Lowenstein PR; Castro MG
    Curr Top Med Chem; 2005; 5(12):1151-70. PubMed ID: 16248789
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Imaging Glioblastoma Posttreatment: Progression, Pseudoprogression, Pseudoresponse, Radiation Necrosis.
    Strauss SB; Meng A; Ebani EJ; Chiang GC
    Neuroimaging Clin N Am; 2021 Feb; 31(1):103-120. PubMed ID: 33220823
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pseudoprogression in patients with glioblastoma: added value of arterial spin labeling to dynamic susceptibility contrast perfusion MR imaging.
    Choi YJ; Kim HS; Jahng GH; Kim SJ; Suh DC
    Acta Radiol; 2013 May; 54(4):448-54. PubMed ID: 23592805
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Physiologic MRI for assessment of response to therapy and prognosis in glioblastoma.
    Shiroishi MS; Boxerman JL; Pope WB
    Neuro Oncol; 2016 Apr; 18(4):467-78. PubMed ID: 26364321
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pseudoprogression versus true progression in glioblastoma patients: A multiapproach literature review. Part 2 - Radiological features and metric markers.
    Le Fèvre C; Constans JM; Chambrelant I; Antoni D; Bund C; Leroy-Freschini B; Schott R; Cebula H; Noël G
    Crit Rev Oncol Hematol; 2021 Mar; 159():103230. PubMed ID: 33515701
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Distinguishing glioma recurrence from treatment effect after radiochemotherapy and immunotherapy.
    Yang I; Huh NG; Smith ZA; Han SJ; Parsa AT
    Neurosurg Clin N Am; 2010 Jan; 21(1):181-6. PubMed ID: 19944976
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Glioblastoma Recurrence Versus Treatment Effect in a Pathology-Documented Series.
    Himes BT; Arnett AL; Merrell KW; Gates MJ; Bhargav AG; Raghunathan A; Brown DA; Burns TC; Parney IF
    Can J Neurol Sci; 2020 Jul; 47(4):525-530. PubMed ID: 32077389
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combined iron oxide nanoparticle ferumoxytol and gadolinium contrast enhanced MRI define glioblastoma pseudoprogression.
    Barajas RF; Hamilton BE; Schwartz D; McConnell HL; Pettersson DR; Horvath A; Szidonya L; Varallyay CG; Firkins J; Jaboin JJ; Kubicky CD; Raslan AM; Dogan A; Cetas JS; Ciporen J; Han SJ; Ambady P; Muldoon LL; Woltjer R; Rooney WD; Neuwelt EA
    Neuro Oncol; 2019 Mar; 21(4):517-526. PubMed ID: 30277536
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The predictive value of absolute lymphocyte counts on tumor progression and pseudoprogression in patients with glioblastoma.
    Xi J; Hassan B; Katumba RGN; Khaddour K; Govindan A; Luo J; Huang J; Campian JL
    BMC Cancer; 2021 Mar; 21(1):285. PubMed ID: 33726710
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Recurrent glioblastoma versus late posttreatment changes: diagnostic accuracy of O-(2-[18F]fluoroethyl)-L-tyrosine positron emission tomography (18F-FET PET).
    Bashir A; Mathilde Jacobsen S; Mølby Henriksen O; Broholm H; Urup T; Grunnet K; Andrée Larsen V; Møller S; Skjøth-Rasmussen J; Skovgaard Poulsen H; Law I
    Neuro Oncol; 2019 Dec; 21(12):1595-1606. PubMed ID: 31618420
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Imaging Glioblastoma Posttreatment: Progression, Pseudoprogression, Pseudoresponse, Radiation Necrosis.
    Strauss SB; Meng A; Ebani EJ; Chiang GC
    Radiol Clin North Am; 2019 Nov; 57(6):1199-1216. PubMed ID: 31582045
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of pseudoprogression in patients with glioblastoma multiforme using dynamic magnetic resonance imaging with ferumoxytol calls RANO criteria into question.
    Nasseri M; Gahramanov S; Netto JP; Fu R; Muldoon LL; Varallyay C; Hamilton BE; Neuwelt EA
    Neuro Oncol; 2014 Aug; 16(8):1146-54. PubMed ID: 24523362
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Radiation Necrosis, Pseudoprogression, Pseudoresponse, and Tumor Recurrence: Imaging Challenges for the Evaluation of Treated Gliomas.
    Zikou A; Sioka C; Alexiou GA; Fotopoulos A; Voulgaris S; Argyropoulou MI
    Contrast Media Mol Imaging; 2018; 2018():6828396. PubMed ID: 30627060
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment-related changes in glioblastoma: a review on the controversies in response assessment criteria and the concepts of true progression, pseudoprogression, pseudoresponse and radionecrosis.
    Delgado-López PD; Riñones-Mena E; Corrales-García EM
    Clin Transl Oncol; 2018 Aug; 20(8):939-953. PubMed ID: 29218626
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.